Compare McKesson Corporation (MCK) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Oxford Lane Capital Corp — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Oxford Lane Capital Corp trades at $8.59 (market cap $835.71M). The key difference: McKesson Corporation is far larger — about 129.8× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.15%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Oxford Lane Capital Corp for 49 Days on average.
| MCK | OXLC | |
|---|---|---|
Market Cap | $108.46B | $835.71M |
Volume | 712,607 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $995.69 | $16.74 |
52-Week Low | $725.17 | $8.15 |
Typical Hold Time | 74 Days | 49 Days |
Enterprise Value | $115.00B | $1.23B |
Dividend Yield | 0.4% | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
OXLC trades at $8.46, down 2.53% on the day, with a bearish technical outlook indicated by moving averages and oscillators. Recent earnings misses and a sharp decline in 2026 revenue and net income highlight fundamental challenges, though the stock trades below book value. The company maintains a regular dividend payout, but negative cash flow from operations and high interest expenses pose sustainability concerns.
The outlook is cautious due to deteriorating profitability and bearish sentiment, though deep valuation discounts may attract contrarian investors. Key risks include earnings volatility, dividend coverage, and market sentiment shifts. Analyst consensus is mixed, with half recommending buy but technicals signaling sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
